Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1213790 dose-ranging study for prevention of venous thromboembolism after total knee arthroplasty
2016-002681-31Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osocimab in venous thromboembolism (VTE) (3 arms), sponsored by Bayer. Primary endpoint: Composite venous thromboembolism endpoint. Started May 2017; status: completed.
02
Drugs
osocimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2016-002681-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002681-31.